Skip To The Main Content
2020 Quality Regulations

PDA Europe Virtual Conference - Quality and Regulations

Jun 09 - Jun 11, 2020
Central Europe Standard Time | Online
  • Conference
  • Virtual
  • Europe
  • Online
Program Highlights

Dear Colleague,

The manufacture of drugs and drug products is one of the most closely regulated activity in the industry. The core of Good Manufacturing Practice is defined and determined by a variety of guidelines and regulations issued and updated regularly by national and international authorities. These have direct implications for the development, manufacturing, and reliable distribution of pharmaceutical parenteral products.

This and more will be the focus of the 2020 PDA Europe Quality and Regulations conference, presented as a virtual conference. 

By joining this two-day event, attendees will ensure to receive the most current and thorough information on recent and most important changes in the regulatory landscape.

In the era of breakthrough medicinal therapies and accelerated R&D, Lifecycle and Change Management, Knowledge and Risk Management as well as availability of these drugs become pivotal milestones. Dive into the new decade with PDA by exploring Digital Solutions in Quality and don’t miss out on learnings on impurity controls and control strategy!


The Conference Chairs
Barbara Allen, PhD, Eli Lilly
Prof. Frank Hallinan, PhD, Consultant



Barbara Allen, Eli Lilly, Chair
Frank Hallinan, former IMBChair
Vinny Browning III, Amgen
Karin Baer, Boehringer Ingelheim
Karen Casey, Janssen J&J
Graham Cook, Pfizer
Patrick Costello, Abbvie
Anne Hayes, HPRA, PIC/S
Toni Manzano
, Bigfinite
Ruth Miller, PDA
Peter Reichert, Zelect
Falk Klar, PDA Europe
Sylvia Becker, Senior Manager Programs & Events, PDA Europe


  • Day 1
  • Day 2
  • Day 3
  • Tuesday, 09 June 2020

    Module I: Welcome & Regulatory Updates
    10:30-12:45 CEST

    This decade will see unprecedented change in the number of new type of medicines and the technology and data tools to manufacture them. In addition, reliable supply of quality medicines in a global environment will continue to be core to the industry. In this session, industry and regulatory leaders will share their insights on the key anticipated changes and how quality assurance and regulatory focus will move with them. Subsequent sessions will explore the themes raised and experts will share relevant experiences and ideas.
    Welcome and Opening Remarks Falk Klar, PhD, PDA Europe
    Welcome from the PDA President Richard Johnson, PDA
    Welcome from PDA Board of Directors Chair Jette Christensen, BoD

    Program Preview: What's Planned for the next Days

    Conference Chairs
    Barbara Allen, PhD, Eli Lilly
    Prof. Frank Hallinan, PhD, Consultant

    Regulatory Updates

    Barbara Allen, Eli Lilly

    HPRA & EMA Strategy 2020 – 2025 Lorraine Nolan, CEO of HPRA
    Manufacturing in a New Decade and What it Means for Regulations & Quality Anil Sawant, Merck Sharp Dohme, Senior Vice President, Global Quality Compliance
    Quality Culture – The Pathway to the Future Anthony Morandi, AstraZeneca, Vice President of Corporate Quality & Strategy

    Live Q & A, Discussion


    Break and Virtual Exhibition
    12:45-14:15 CEST


    Module II: Quality Risk Management & Knowledge Management
    14:15-17:00 CEST

    QRM has been an integral enabling element of the pharmaceutical quality system (PQS) since the adoption of ICH Q9. Despite it now being widely used, many uncertainties remain regarding QRM, for example, formal vs informal, enabler or, QS tool. This session will examine QRM in its role of an enabler of the PQS as outlined in ICH Q10. This will include the perspective of an experienced regulator with a long standing interest in QRM bolstered by multiple publications on the topic and from an industry expert who also is author of important publications on the topic. We anticipate that attendees at the session will leave with a deeper understanding of how QRM is most appropriately and effectively used within their organization’s Quality System.

    Q10-Enablers: Quality Risk Management & Knowledge Management

    Frank Hallinan, Consultant

    A Regulator's Perspective on Quality Risk Management & Knowledge Management after 12 Years Kevin O'Donnell, HPRA
    An Industry Perspective on How Quality Risk Management Does and Will Enable an Effective Pharmaceutical Quality System Ghada Haddad, Merck Sharp Dohme
    A Framework for Realization of Knowledge Management as a PQS Enabler Marty Lipa, Technological University Dublin
    How Does Knowledge Management Enable a PQS and How Management Review Supports It Michele Simone, Bracco
    N-nitrosamine Impurities: Actions, Lessons Learned and Next Steps Oliver Meier, Novartis

    Live Q & A, Discussion


    Virtual Networking Event
    17:00-18:00 CEST

    Meet your peers in one of our group chats

  • Chatroom I: Exchange Forum for Best Practice during COVID_19
  • Chatroom II: Delve Deeper into the Hot Topics of Today's Discussions
  • Chatroom III: Share Your Craziest Experience and Newly Discovered Hobbies during COVID_19 Lockdown
  • Exchange Forum: Meet the Regulator

  • Wednesday, 10 June 2020

    Module III: Digital Solutions & Quality
    10:00-12:10 CEST

    The complexity associated with manufacturing of biopharmaceuticals has increased because of the intrinsic variability of the materials and interconnected processes involved. Control of these multivariate operations requires to be managed under a quality approach supported by technology and modern systems that adequately manage to cope with this reality. This session will share and discuss experiences implementing quality from new perspectives.

    Digital Solutions & Quality

    Toni Manzano, BigFinite

    Continued Process Verification (CPV) of the Future:
    Better Understanding of the Upstream Process

    Francisco Valero,
    Universitat Autonoma de Barcelona

    Digital Change Implementation in the Context of CMC Transformation

    David O'Grady,

    Data Integrity – Mission Unaccomplished

    Siegfried Schmitt,

    Leveraging Modern Technologies:
    Improving Overall Product Quality and Meeting Regulatory Compliance - Case Study

    Robert Gaertner,

    Live Q & A, Discussion


    Break and Virtual Exhibition
    12:10-14:00 CEST


    Module IV: Regulatory Oversight
    14:00-16:45 CEST

    Regulatory oversight is an integral part of quality assurance. This session will look at the evolution of inspections, pharmacopeia and compliance.

    Regulatory Oversight

    Patrick Costello, AbbVie

    Irish Regulatory Perspective on Inspections

    Paul Sexton,

    The Evolving Regulatory Environment:
    PIC/S - Where We Are and Where We Move To

    Anne Hayes,

    The Evolution of Compliance and Cost of Quality

    Rick L. Friedman,
    US FDA

    Updates on Monographs and Chapters & Recent Developments in Biologics

    Maura Kibbey,
    United States Pharmacopeia

    European Updates for the New Decade

    Cathie Vielle,
    European Directorate for the Quality of
    Medicines & HealthCare

    Live Q & A, Discussion


    Virtual Networking Event
    16:45-17:30 CEST

    Meet your peers in our open chat

  • Thursday, 11 June 2020

    Module V: Life Cycle Management and Change Management
    10:00-12:30 CEST

    Ensuring continued quality and supply requires updates and changes. This session will explore how change management will evolve over the coming decade.

    Life Cycle Management and Change Management

    Graham Cook, Pfizer

    Control Strategies:
    A Foundation for Quality and Regulatory Flexibility

    David Churchward,

    ICH Q12 Implementation from a
    Chemistry, Manufacturing and Controls Perspective

    Mihai Bilanin,

    Demonstrating Effectiveness of PQS for PAC

    Emma Ramnarine,

    What is Data Integrity in a QMS

    Travis Frick,

    PDA Tech Report 65 on Tech Transfer

    Beth J. Haas,

    Live Q & A, Discussion


    Break and Virtual Exhibition
    12:30-14:00 CEST


    Module VI: Global Quality Assurance In The New Decade
    14:00-16:30 CEST

    The assurance of quality is based on robust control strategy and an effective quality management system, supported by regulatory authority oversight. In this session, Industry and regulatory authority leaders will share how assurance continues to evolve, based on learning from events and from proactive planning.

    Global Quality Assurance In The New Decade

    Karin Baer, Boehringer-Ingelheim

    The Global Supply Chain and US Regulatory Trends

    Ashley B. Boam,
    US FDA

    An Industry Approach to Drug Shortage Prevention

    Stephan Roenninger,

    Managing the Digitalization:
    Demonstrate how the PQS is Contributing to this Transformation Process

    Padraig Landers,
    Bristol-Myers Squibb

    Quality: Pathway to the Future

    Anders Vinther,
    Intarcia Therapeutics

    Live Q & A, Discussion

    Conference Summary

    Conference Chairs,
    Barbara Allen, Eli Lilly,
    Frank Hallinan, Consultant

    Chair Awards, Closing Remarks and Farewell

    Falk Klar, PDA Europe

Highlighted Speakers

Ashley B. Boam
Ashley B. Boam
David M. Churchward
David M. Churchward
Maura Kibbey
Maura Kibbey
United States Pharmacopeia
Oliver Meier
Oliver Meier
Anthony Morandi
Anthony Morandi
Lorraine Nolan
Lorraine Nolan
Health Products Regulatory Authority (HPRA)
Anil Sawant
Anil Sawant
Merck & Co., Inc. / MSD
Cathie Vielle
Cathie Vielle
  • Virtual Event FAQ

Who Should Attend

  • Quality Assurance
  • Quality Affairs/External Affairs
  • Regulatory Affairs
  • Consultants Regulatory agency employees from international agencies Manufacturing
  • Quality Control

Registration Fees

Register Now
Registration Type Three Day Access One Day Access *
Member, Non-Member, Young Professional, Poster-Presenter € 949 € 449
Govern./Health Authority/Academic € 699 € 449

* To book a one-day access, please contact [email protected].

Got a Question? We have answers

Contact Us
Become a Sponsor

Interested in becoming a sponsor? Learn about opportunities and benefits.

Request Information


Become an Exhibitor

Interested in becoming an exhibitor? Learn about opportunities and benefits.

Request Information

Attendee List Email Scam

Unfortunately, emails are circulating that offer to sell attendee lists for many of PDA’s conferences and events. These emails are sent by scammers.

Note: PDA does not sell its exhibitor or attendee lists, and no third-party is authorized to distribute or sell any lists related to our events. Statements claiming to offer our attendee lists are fraudulent. If you receive emails that propose to sell PDA conference attendee lists, do not engage with the sender and delete the message immediately.

Media Partners


Program Inquiries
Exhibition Inquiries
Course Inquiries
Registration Customer Care

Tel: +1 (301) 656-5900 ext. 115
[email protected]

PDA Members Save Substantially